Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups

European Journal of Pharmaceutical Sciences

Volumn 46, Issue 1-2, 2012, Pages 86-99

  Kolhatkar, Vidula ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

ASBT; Bile acid; Inhibitor; NTCP; Prodrug; Substrate

Indexed keywords

APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; BILE ACID; BILE ACID CONJUGATE; CARRIER PROTEIN; HYDROXYL GROUP; PRODRUG; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ACYLATION; ARTICLE; BILE ACID SYNTHESIS; CELL CULTURE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DRUG TARGETING; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CELL LINE; DRUG DELIVERY SYSTEMS; HUMANS; ILEUM; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PRODRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS; TAUROCHOLIC ACID;

EID: 84859218893     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.02.012     Document Type: Article

References (39)

1. Alrefai, W.A., Gill, R.K., 2007. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24, 1803-1823. (Pubitemid 47389235)
2. Balakrishnan, A., Hussainzada, N., Gonzalez, P., Bermejo, M., Swaan, P.W., Polli, J.E., 2007. Bias in estimation of transporter kinetic parameters from overexpression systems: interplay of transporter expression level and substrate affinity. J. Pharmacol. Exp. Ther. 320, 133-144. (Pubitemid 46025728)
3. Balakrishnan, A., Polli, J.E., 2006. Apical sodium dependent bile acid transporter (ASBT;SLC10A2): a potential prodrug target. Mol. Pharm. 3, 223-230. (Pubitemid 44021430)
4. Balakrishnan, A., Sussman, D.J., Polli, J.E., 2005. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm. Res. 22, 1269-1280. (Pubitemid 41176030)
5. Balakrishnan, A., Wring, S.A., Coop, A., Polli, J.E., 2006a. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol. Pharm. 3, 282-292. (Pubitemid 44021434)
6. Balakrishnan, A., Wring, S.A., Polli, J.E., 2006b. Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm. Res. 23, 1451-1459. (Pubitemid 43993808)
7. Banerjee, A., Swaan, P.W., 2006. Membrane topology of human ASBT (SLC10A2) determined by dual label epitope insertion scanning mutagenesis. New evidence for seven transmembrane domains. Biochemistry 45, 943-953. (Pubitemid 43122258)
8. Baringhaus, K.H., Matter, H., Stengelin, S., Kramer, W., 1999. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter. J. Lipid Res. 40, 2158-2168. (Pubitemid 30017517)
9. Bemis, G.W., Murcko, M.A., 1996. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887-2893. (Pubitemid 26251026)
10. Bhat, L., Jandeleit, B., Dias, T.M., Moors, T.L., Gallop, M.A., 2005. Synthesis and biological evaluation of novel steroidal pyrazoles as substrates for bile acid transporters. Bioorg. Med. Chem. Lett. 15, 85-87. (Pubitemid 39575788)
11. Bortolini, O., Fantin, G., Fogagnolo, M., Mari, L., 2006. Two-way enantioselective control in the epoxidation of alkenes with the keto bile acid-Oxone® system. Tetrahedron 62, 4482-4490.
12. Gonzalez, P.M., Polli, J.E., 2008. Impact of impurity on kinetic estimates from transport and inhibition studies. J. Pharmacol. Exp. Ther. 326, 296-305. (Pubitemid 351872138)
13. Gonzalez, P.M., Acharya, C., Mackerell Jr, A.D., Polli, J.E., 2009. Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. Pharm. Res. 26, 1665-1678.
14. Hagenbuch, B., Meier, P.J., 1994. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J. Clin. Invest. 93, 1326-1331. (Pubitemid 24087193)
15. Han, Y.H., Busler, D., Hong, Y., Tian, Y., Chen, C., Rodrigues, A.D., 2010. Transporter studies with the 3-O-sulfate conjugate of 17alpha- ethinylestradiol: assessment of human liver drug transporters. Drug Metab. Dispos. 38, 1072-1082.
16. Ho, R.H., Tirona, R.G., Leake, B.F., Glaeser, H., Lee, W., Lemke, C.J., Wang, Y., Kim, R.B., 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression and pharmacogenetics. Gastroenterology 130, 1793-1806.
17. Kolhatkar, V., Diao, L., Acharya, C., MacKerell, A.D., Polli, J.E., 2012. Identification of novel non-steroidal compounds as substrates or inhibitors of hASBT. J. Pharm. Sci. 101, 116-126.
18. Kolhatkar, V., Polli, J.E., 2010. Reliability of inhibition models to correctly identify type of inhibition. Pharm. Res. 27, 2433-2445.
19. Kramer, W., 2011. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery. Biol. Chem. 392, 77-94.
20. Kramer, W., Stengelin, S., Baringhaus, K.H., Enhsen, A., Heuer, H., Becker, W., Corsiero, D., Girbig, F., Noll, R., Weyland, C., 1999. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters. J. Lipid Res. 40, 1604-1617. (Pubitemid 29418701)
21. Kramer, W., Wess, G., Neckermann, G., Schubert, G., Fink, J., Girbig, F., Gutjahr, U., Kowalewski, S., Baringhaus, K.H., Boger, G., 1994. Intestinal absorption of peptides by coupling to bile acids. J. Biol. Chem. 269, 10621-10627. (Pubitemid 24198266)
22. Kramer, W., Wess, G., Schubert, G., Bickel, M., Girbig, F., Gutjahr, U., Kowalewski, S., Baringhaus, K.H., Enhsen, A., Glombik, H., 1992. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. 267, 18598-18604.
23. Kramer, W., Wess, G., Enhsen, A., Falk, E., Hoffmann, A., Neckermann, G., Schubert, G., Urmann, M., 1997. Modified bile acids as carriers for peptides and drugs. J. Controlled Release 46, 17-30. (Pubitemid 27110884)
24. Kritchevsky, D., Poli, G., Scolastico, C., Sirtori, C.R., 1986. Novel derivatives of 3α7 alpha-dihydroxy-5 beta-cholan-24-oic acid (chenodeoxycholic acid) and 3 alpha, 7 beta-dihydroxy-5 beta-cholan-24-oic acid (ursodeoxycholic acid). Steroids 47, 41-48. (Pubitemid 17203905)
25. Kullak-Ublick, G.A., Glasa, J., Boker, C., Oswald, M., Grutzner, U., Hagenbuch, B., Stieger, B., Meier, P.J., Beuers, U., Kramer, W., Wess, G., Paumgartner, G., 1997. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113, 1295-1305. (Pubitemid 27418984)
26. Kullak-Ublick, G.A., Stieger, B., Meier, P.J., 2004. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126, 322-342. (Pubitemid 38040747)
27. Rais, R., Acharya, C., Mackerell, A.D., Polli, J.E., 2010a. Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol. Pharm. 7, 2240-2254.
28. Rais, R., Acharya, C., Tririya, G., Mackerell, A.D., Polli, J.E., 2010b. Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter. J. Med. Chem. 53, 4749-4760.
29. Rais, R., Fletcher, S., Polli, J.E., 2011. Synthesis and invitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). J. Pharm. Sci. 100, 1184-1195.
30. Rais, R., Gonzalez, P.M., Zheng, X., Wring, S.A., Polli, J.E., 2008. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J. 10, 596-605.
31. Sievanen, E., 2007. Exploitation of bile acid transport systems in prodrug design. Molecules 12, 1859-1889.
32. Swaan, P.W., Hillgren, K.M., Szoka Jr, F.C., Oie, S., 1997. Enhanced transepithelial transport of peptides by conjugation to cholic acid. Bioconjug. Chem. 8, 520-525. (Pubitemid 27347559)
33. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., Schoonjans, K., 2008. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678-693.
34. Trauner, M., Graziadei, I.W., 1999. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther. 13, 979-996.
35. Tserng, K.Y., Hachey, D.L., Klein, P.D., 1977. An improved procedure for the synthesis of glycine and taurine conjugates of bile acids. J. Lipid Res. 18, 404-407. (Pubitemid 8114149)
36. Weinman, S.A., Carruth, M.W., Dawson, P.A., 1998. Bile acid uptake via the human apical sodium-bile acid cotransporter is electrogenic. J. Biol. Chem. 273, 34691-34695. (Pubitemid 29028157)
37. Zhang, E.Y., Phelps, M.A., Cheng, C., Ekins, S., Swaan, P.W., 2002. Modeling of active transport systems. Adv. Drug Deliv. Rev. 54, 329-354.
38. Zheng, X., Pan, Y., Acharya, C., Swaan, P.W., Polli, J.E., 2010. Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid. Bioconjug. Chem. 21, 2038-2048.
39. Zheng, X., Polli, J.E., 2010. Synthesis and invitro evaluation of potential sustained release prodrugs via targeting ASBT. Int. J. Pharm. 396, 111-118.